The Friday weight loss program offers a route to lasting weight loss and metabolic well-being through an online platform. This program leverages compounded GLP-1 medications and personalized healthcare to support individuals in achieving their weight loss goals.
Understanding the Friday Weight Loss Program
The Friday program distinguishes itself as a provider of GLP-1 medications with a transparent, single-price model. This approach eliminates concerns about hidden costs, offering a straightforward path to weight loss. There are no membership fees, sign-up fees, or lab fees.
What to Expect After the Eligibility Quiz
Upon completing the eligibility quiz, those who qualify can schedule a prescription fill. This can be done via a video consultation or, depending on the state, without a video consultation. After selecting the preferred prescription fill method, participants will be prompted to sign up for a monthly subscription service. Once payment is processed, a password must be created for the account. The final step is to complete an initial health history intake form, which should be done as soon as possible to avoid delays in the treatment plan.
The Initial Appointment and Personalized Health Plan
During the first appointment, the healthcare provider will discuss health goals, review medical history, order any necessary lab tests, and potentially prescribe medication if deemed appropriate. The provider will collaborate with the patient to create a personalized health plan. This plan may include lifestyle recommendations and a prescription for weight loss medication.
Regular Check-Ins and Progress Monitoring
After starting weight loss medication, regular check-ins with the provider can be scheduled. Initially, these visits typically occur once a month. During these check-ins, the provider will assess weight loss progress, monitor medication tolerance, arrange follow-up lab tests or prescription refills, and adjust the care plan as needed.
Read also: Weight Loss Guide Andalusia, AL
GLP-1 Medications: The Science Behind Weight Loss
Glucagon-like peptide-1 (GLP-1) medications have emerged as a significant tool in the fight against obesity. These drugs mimic the effects of the naturally occurring GLP-1 hormone, which plays a crucial role in regulating appetite and blood sugar levels.
How GLP-1 Medications Work
GLP-1 medications work by:
- Increasing feelings of fullness: GLP-1s slow down the emptying of the stomach, leading to a prolonged feeling of satiety.
- Reducing appetite: By acting on the brain, GLP-1s can decrease appetite and cravings.
- Improving blood sugar control: GLP-1s stimulate insulin release and inhibit glucagon secretion, helping to regulate blood sugar levels.
Weight Loss Expectations with GLP-1 Medications
Weight loss outcomes can vary based on individual factors such as initial weight, medical conditions, lifestyle adjustments, and the specific medication used. Individuals who have taken GLP-1 medications for an extended period (68 weeks or more) and have adopted healthy lifestyle choices have reported weight reductions of up to 15% from their initial body weight. Newer medications that act as both GLP-1 and GIP agonists have demonstrated even greater potential, with average weight reductions of 20%.
Compounded GLP-1 Medications
The Friday program uses compounded GLP-1 medications, which are sourced from highly regulated pharmacies. Compounded medications offer an alternative to brand-name drugs, potentially at a lower cost. Compounded GLP-1 medications available include:
- Compounded GLP-1/GIP (Contains: Tirzepatide).
- Compounded GLP-1 (Contains: Semaglutide).
Eligibility for Weight Loss Medications
Not everyone is a suitable candidate for weight loss medications. Healthcare providers consider several factors to determine eligibility.
Read also: Beef jerky: A high-protein option for shedding pounds?
Qualifying Criteria
Generally, individuals who meet the following criteria may be considered eligible:
- Age 18-74 years old.
- Overweight (BMI > 27) or obesity (BMI > 30).
- Seeking maintenance therapy with a BMI > 22, and if their current BMI < 27, have a history of obesity or overweight and have previously been on a GLP-1 within the past 12 months.
What if BMI Falls Below 27?
If a participant's BMI drops below 27, it may indicate that GLP-1 medications are no longer necessary. In this case, the healthcare provider will reassess eligibility to determine if continuation in the program is appropriate.
Dr. David Kessler's Insights on Weight Loss and GLP-1 Drugs
Dr. David A. Kessler, former Commissioner of the Food and Drug Administration, has personal and professional experience with weight management and GLP-1 drugs. His insights provide valuable context for understanding the role of these medications in achieving a healthy weight.
The Impact of the Food Environment
Kessler emphasizes the role of the modern food environment in driving weight gain. Foods high in salt, sugar, and fat are readily available and engineered to manipulate the brain's reward system, making it difficult to resist overconsumption. He refers to these foods as "ultra-formulated" and suggests that they can activate the same reward centers as addictive drugs.
Visceral Fat: A Key Indicator of Health Risk
Kessler highlights that being overweight, as measured by BMI, is not always an accurate indicator of health. Instead, he points to visceral fat, the fat found around abdominal organs, as a more critical driver of metabolic disease. Visceral fat releases inflammatory substances that can lead to organ damage and various health problems.
Read also: Inspiring Health Transformation
The Importance of Mindful Eating on GLP-1 Drugs
GLP-1 drugs can help individuals relearn how to eat, but this process may involve some discomfort. These medications suppress appetite and increase feelings of fullness, which can sometimes be perceived as unpleasant. However, this effect can also lead to healthier eating habits as patients become more attuned to their body's signals.
Potential Side Effects and the Need for Medical Supervision
Kessler stresses the importance of working with a physician who can monitor progress and adjust medication dosages as needed. He also recommends consulting a dietician or nutritionist to develop healthy eating habits. Potential side effects of GLP-1 drugs include nausea, vomiting, and constipation. In rare cases, more severe complications such as intestinal obstruction can occur.
The Risks of Compounded GLP-1s
Kessler expresses concerns about the risks associated with compounded GLP-1 medications, which may not be subject to the same rigorous quality control standards as brand-name drugs. He notes that the active ingredients in compounded drugs are often manufactured abroad and distributed through complex supply chains, making it difficult to ensure their safety and efficacy.
The Need for Guidance on Discontinuing GLP-1 Drugs
Kessler points out that there is limited guidance available on how to safely and effectively discontinue GLP-1 drugs. He emphasizes the importance of working with a doctor to gradually reduce the dosage and manage any returning appetite or cravings.
FDA Approval of Zepbound (Tirzepatide)
The Food and Drug Administration (FDA) has approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity or overweight and at least one weight-related condition. Zepbound, used in conjunction with a reduced-calorie diet and increased physical activity, activates GLP-1 and GIP receptors to reduce appetite and food intake.
Clinical Trial Results
Clinical trials have demonstrated Zepbound's effectiveness in promoting weight reduction and maintenance. In a study of adults without diabetes, the average body weight at the start of the trial was 231 pounds (105 kg), and the average body mass index was 38 kg/m2. In adults with type 2 diabetes, the average body weight was 222 pounds (101 kg), and the average body mass index was 36 kg/m2.
Warnings and Precautions
Zepbound carries warnings for potential risks, including thyroid C-cell tumors (observed in rats), pancreatitis, gallbladder problems, hypoglycemia, acute kidney injury, diabetic retinopathy, and suicidal behavior or thinking. It should not be used in patients with a history of severe allergic reaction to tirzepatide or any of its other ingredients.